United Kingdom Liquid Biopsy Market to be Dominated by Oncological Application Through 2028
Increasing
prevalence of cancer and PCR technologies are expected to drive the United
Kingdom Liquid Biopsy Market in the forecast period, 2024-2028.
According to TechSci Research
report, “United
Kingdom Liquid Biopsy Market – By Region, Competition
Forecast and Opportunities, 2018-2028,” the United Kingdom
Liquid Biopsy Market is anticipated to grow at a significant rate in the
forecast period of 2024-2028. The Liquid Biopsy Market in the United Kingdom is
witnessing significant growth, driven by the increasing prevalence of cancer
and the need for early cancer detection. One of the key factors driving the
growth of the liquid biopsy market in the United Kingdom is the increasing
availability and adoption of cutting-edge technologies. Next-generation
sequencing (NGS), for instance, has emerged as a powerful tool in liquid
biopsy, enabling the detection and analysis of genetic alterations and
biomarkers associated with various diseases. NGS allows for the identification
of minute quantities of circulating tumor DNA (ctDNA) in the bloodstream,
providing valuable information about tumor mutations and assisting in treatment
decision-making. The incorporation of NGS into liquid biopsy workflows has
significantly enhanced the sensitivity and specificity of disease detection,
making it a game-changer in personalized medicine. The increasing collaboration
between academic institutions, research organizations, and healthcare providers
has also contributed to the growth of the liquid biopsy market in the United
Kingdom. Such collaborations foster knowledge exchange, accelerate technology
development, and promote the translation of research findings into clinical
practice, thereby augmenting the growth of the United Kingdom Liquid Biopsy
Market in the forecast period. However, the high cost of liquid biopsy and the
lack of skilled professionals can be barriers to access for some individuals,
particularly those from low-income backgrounds, which may hamper the market's
growth in the forecast period.
Browse over XX market
data Figures spread through XX Pages and an in-depth TOC on “United Kingdom Liquid Biopsy Market”
The United
Kingdom Liquid Biopsy Market is segmented into Offering, Technology, Workflow,
Sample, Circulating Biomarker, Application, End User, Region and Competitive
Landscape.
Based on
Offering, the market is divided into Testing Service, Kits, Platform, and Other
Consumables. The Testing Service segment is expected to witness a rise over the
forecast period. This is attributed to the prevalence of cancer cases and
rising awareness regarding cancer diagnostics, which is anticipated to support
market growth in the future.
Based on
Technology, the market is divided into Polymerase Chain Reactions, Next
Generation Sequencing, and Others. Next Generation Sequencing is expected to
witness a rise over the forecast period. This is attributed to its better
results in cancer detection.
Based on
Workflow, the market is divided into Sample Preparation, Library Preparation,
Sequencing, and Data Analysis & Management. Data Analysis & Management
is expected to witness a rise over the forecast period. This is attributed to
drilling out the root cause of disease that helps in the treatment
prescription.
Based on Sample,
the market is divided into Blood, Urine, Saliva, and Others. Blood segment is
expected to witness a rise over the forecast period. This is attributed to the
detection of cancerous tumors and cancer cell DNA from the blood sample.
Based on
Circulating Biomarker, the market is divided into Circulating Tumor Cells
(CTCs), Cell Free Nucleic Acids, Exosomes & Extracellular Vesicles, and
Others. Circulating Tumor Cells (CTCs) are expected to witness a rise over the
forecast period. The market demand is being driven by the rising incidence of
cancer and the development of ctDNA-based liquid biopsy analysis, which can
predict tumor progression.
Based on
Application, the market is divided into Oncological and Non-Oncological.
Oncological Liquid Biopsy is expected to witness a rise over the forecast
period. This is attributed to the detection of tumor cells by incorporating liquid
biopsy.
Based on End User,
the market is divided into Clinical Laboratories, Academic & Research
Institutes, and Pharmaceutical & Biotechnology Companies. Clinical
Laboratories are expected to witness a rise over the forecast period. This can
be attributed to the availability of both inpatient and outpatient medication
facilities and certified healthcare professionals leading to the growth of the
United Kingdom Liquid Biopsy market.
Major companies
operating in United Kingdom Liquid Biopsy Market are:
- F. Hoffmann-La Roche AG
- Thermo Fisher Scientific, Inc
- PerkinElmer Inc.
- Illumina, Inc.
- QIAGEN NV
- Dxcover Limited
- Abcodia Ltd
- Sysmex Corporation
- Bio-Rad Laboratories, Inc.
Download Free Sample Report
Customers can also request 10% free customization in this
report.
“The United Kingdom Liquid Biopsy Market
is poised for significant growth in the coming years due to the escalating
prevalence of cancer among the population in the nation. The burgeoning
technological advancements in the medical diagnostics industry and the rising
number of hospitals in the country will drive a notable market segment in the
United Kingdom. Furthermore, the increasing healthcare investments and
government initiatives for research and innovation will bolster the market's
growth trajectory, which is anticipated to continue flourishing until
2028," stated Mr. Karan Chechi, Research Director at TechSci Research, a
research-based global management consulting firm.
“United Kingdom Liquid
Biopsy Market By Offering (Testing Service, Kits, Platform, Other
consumables), By Technology (Polymerase Chain Reactions (PCR), Next Generation
Sequencing (NGS), Others), By Workflow (Sample Preparation, Library
Preparation, Sequencing, Data Analysis & Management), By Sample (Blood,
Urine, Saliva, Others), By Circulating Biomarkers (Circulating Tumor Cells
(CTCs), Cell-free Nucleic Acids, Exosomes & Extracellular Vesicles, Others),
By Application (Oncological and Non-oncological), By End User (Clinical
Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology
Companies), By Region, Competition Forecast & Opportunities, 2018-2028F,” has evaluated the future
growth potential of United Kingdom Liquid Biopsy Market and provides statistics
& information on market size, structure, and future market growth. The
report intends to provide cutting-edge market intelligence and help decision
makers take sound investment decisions. Besides, the report also identifies and
analyzes the emerging trends along with essential drivers, challenges, and
opportunities in United Kingdom Liquid Biopsy Market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Web: https://www.techsciresearch.com